Archive for the ‘South Africa’ Category
Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial
Total of 2,784 infants vaccinated in TB efficacy trial evaluating MVA85A
Study results expected to be available as early as mid-2012
ROCKVILLE, Md., Apr 28, 2011
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its joint venture with the University of Oxford (Oxford), the Oxford-Emergent Tuberculosis Consortium [...]
May 2, 2011
Tags: Emergent BioSolutions, South African Tuberculosis Vaccine, Tuberculosis Consortium Vaccinates Posted in: Chief executive officer, Emergent BioSolutions, South Africa 
No Comments